Skip to main content

Market Overview

3Q Upside For Medical Tech. & Hospital Supplies


Piper Jaffray has published a research report on Medical Technology and Hospital Supplies as sales continue to track above expectations, as witnessed in September earnings results.

In the report, Piper Jaffray writes "JNJ: Tracking $24 MM ahead of expectations - Upside in Q3 is being driven
primarily by greater-than-expected share gains and growth by Simponi and Nucynta, albeit on relatively small prior-year comparisons. Additionally, sales of both Concerta and Prezista are tracking above our revenue estimates for the quarter, +$29 mil and +$28 mil, respectively. Offsetting the strength in these product lines is slight weakness in Respirdal Consta and Topamax, $7 mil and $3 mil, respectively, below our estimates.
• ACL: Tracking $39 MM above our estimates - By our analysis, upside for ACL in Q3 continues to be primarily driven by price taken at the beginning of the year and volume growth in Patanol/Pataday and CiproHC/Ciprodex, which are tracking approximately $16 mil and $23 mil, respectively, above our estimates. The rest of ACL's pharma products continue to track slightly above our expectations."

Companies related to this article include:

Alcon, Inc. (NYSE: ACL) $170.18
Johnson & Johnson (NYSE: JNJ) $63.58


Related Articles (ACL + JNJ)

View Comments and Join the Discussion!

Posted-In: alcon Johnson & Johnson Piper JaffrayAnalyst Color Analyst Ratings

Latest Ratings

CMRXHC Wainwright & Co.Maintains18.0
PZZAStephens & Co.Maintains115.0
STAACanaccord GenuityMaintains150.0
DGIICanaccord GenuityMaintains25.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at